Open forum infectious diseases
Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants.
Amparo L Figueroa, Bethany Girard, Darin K Edwards, Arshan Nasir, Kimball Johnson, Steven Hack, Xin Cao, Elizabeth de Windt, Veronica Urdaneta, Frances Priddy, Rituparna Das, David C Montefiori, Spyros Chalkias
Published: 202510.1093/ofid/ofaf705
Abstract
Open AccessIn this ongoing, open-label, phase 3b/4 study, JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines elicited robust neutralization of vaccine-matched variants (JN.1, KP.2) and cross-neutralized JN.1 subvariants circulating during the study (September 2024-November 2024; KP.3.1.1, XEC, LP.8.1) in vaccinated adults, showing reduced cross-neutralization against all subvariants tested. No safety concerns were identified.